Attributes | Values |
---|
rdf:type
| |
Description
| - A review desribes mechanisms by which a host of agents kill (or fail to kill) CSCs. The authors characterize three types of CSCs, namely, breast and prostate cancer and mesothelioma cultured as cancer cell spheres in vitro. The analysis of their stemness is then taken to a new plane by using microarray analysis and the tools of bioinformatics. The tryptophan pathway was the most activated of all pathways whose activation was common to the cancer cells studied suggesting that inhibitors of indoleamine-2,3-dioxygenase (IDO), an enzyme in the tryptophan to N-formyl kynurenin pathway, would be useful for killing CSCs. The authors then develop the principle of mitochondrial targeting by synthesizing a mitochondrially targeted vitamin E succinate [MitoVES] that crosses the mitochondrial inner membrane and acts by targeting the mitochondrial complex II. MitoVES is probably thus far the best characterized agent toxic to CSCs. Two-pronged approach to therapy, therefore, might be desirable.
- A review desribes mechanisms by which a host of agents kill (or fail to kill) CSCs. The authors characterize three types of CSCs, namely, breast and prostate cancer and mesothelioma cultured as cancer cell spheres in vitro. The analysis of their stemness is then taken to a new plane by using microarray analysis and the tools of bioinformatics. The tryptophan pathway was the most activated of all pathways whose activation was common to the cancer cells studied suggesting that inhibitors of indoleamine-2,3-dioxygenase (IDO), an enzyme in the tryptophan to N-formyl kynurenin pathway, would be useful for killing CSCs. The authors then develop the principle of mitochondrial targeting by synthesizing a mitochondrially targeted vitamin E succinate [MitoVES] that crosses the mitochondrial inner membrane and acts by targeting the mitochondrial complex II. MitoVES is probably thus far the best characterized agent toxic to CSCs. Two-pronged approach to therapy, therefore, might be desirable. (en)
|
Title
| - Drugs that kill cancer stem-like cells
- Drugs that kill cancer stem-like cells (en)
|
skos:prefLabel
| - Drugs that kill cancer stem-like cells
- Drugs that kill cancer stem-like cells (en)
|
skos:notation
| - RIV/86652036:_____/11:00375203!RIV12-AV0-86652036
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/86652036:_____/11:00375203
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - Cancer stem cells; 2,3-dioxygenase; MitoVES; inhibitors of indoleamine (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/mistoVydani
| |
http://linked.open...i/riv/nazevZdroje
| - Cancer Stem Cells Theories and Practice
|
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...v/pocetStranKnihy
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...iv/tvurceVysledku
| - Neužil, Jiří
- Dong, L. F.
- Prokopová, Kateřina
- Stantic, M.
- Stapelberg, M.
- Truksa, Jaroslav
- Zobalová, Renata
|
http://linked.open...n/vavai/riv/zamer
| |
number of pages
| |
http://purl.org/ne...btex#hasPublisher
| |
https://schema.org/isbn
| |